CALGB 40603研究分析：Ⅱ/Ⅲ期三阴性乳腺癌新辅助化疗加用卡铂和/或贝伐单抗提高病理完全缓解率

评价者：姚和瑞^a,^b, 游凯云^b, 文献合成者：汪颖^a, 余运芳^a

The Interpretation of CALGB 40603 Trial： The Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Chemotherapy Improve Pathologic Complete Response Rates in StageⅡto Ⅲ Triple Negative Breast Cancer

Reviewers： YAO He-rui^a,^b, You Kai-yun^b, Literature Co-workers： WANG Ying^a, YU Yun-fang^a